CAR T-Cell NJ | John Theurer Cancer Center at HMH   

CAR T-Cell Therapy

A New Form of Immunotherapy

John Theurer Cancer Center is among the few places that offer CAR T-cell therapy. Chimeric Antigen Receptor (CAR) T-cell therapy is a highly promising form of immunotherapy for certain blood cancers and has been researched for nearly a decade. The U.S. Food and Drug Administration has approved CAR T-cell therapy for use in patients up to age 25 with Acute Lymphoblastic Leukemia (ALL) that either came back or stopped responding to other leukemia treatments. It is also approved for use in adult patients with certain types of large B-cell Lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. CAR T-cell therapy is under study and expected to be approved for other types of blood cancer.

What Is CAR T-Cell Therapy?

During the CAR T-cell therapy process, T-cells, or immune cells, are:

  • Removed from the patient through a process called "apheresis" (the separation of T-cells from other components of the blood)
  • Genetically modified, using a disarmed virus, to produce receptors on their surfaces called CARs, allowing the T-cells to recognize and attach to certain targets on cancer cells
  • Grown to larger quantities (hundreds of millions) Returned to the patient, where the CAR T-cells can now find, bind to, and kill cancer cells.
  • Benefits of CAR T-Cell Therapy

Clinical trials of CAR T-cells in blood cancers have shown that even in patients whose cancer came back after multiple treatments, CAR T-cell therapy helped them achieve remissions that lasted for years. Others can live longer without their cancer getting worse, and in some cases can then benefit from curative cancer treatment, such as stem cell transplantation.

CAR T-Cell Therapy Side Effects

CAR T-cell therapy is an intensive treatment that requires specialized expertise and resources to support the patients who receive it. Some patients experience serious side effects, such as fevers or low blood pressure as the modified T-cells become active in the body. Because John Theurer Cancer Center has one of the largest bone marrow transplantation programs in the nation and our doctors have pioneered advances in the use of this treatment, many of our cancer specialists have exceptionally strong backgrounds in immunology and are well-equipped to support patients who develop these side effects.

For More Information

Why Choose Hackensack Meridian Health


John Theurer Cancer Center is part of the National Cancer Institute-designated Georgetown Lombardi Comprehensive Cancer Center.

Premier Cancer Center

U.S. News & World Report has recognized John Theurer Cancer Center at Hackensack University Medical Center as a premier cancer center in New Jersey.

Expansive Network

John Theurer Cancer Center at Hackensack University Medical Center is HMH’s flagship cancer care location. We also have locations across the state providing top-quality care.

We use cookies to improve your experience. Please read our Privacy Policy or click Accept.